1,573 results on '"Senan, S."'
Search Results
2. Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017
3. Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer
4. Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors
5. Artificial intelligence-assisted quantitative CT analysis of airway changes following SABR for central lung tumors
6. Deep Learning and Internet of Things (IoT) Based Monitoring System for Miners
7. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
8. Tumoren van de long, mediastinum en pleura
9. A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors: Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S)
10. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review
11. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
12. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
13. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
14. Splenic Irradiation and Late Volume Changes Following Stereotactic Ablative Radiotherapy (SABR) for Adrenal Tumors
15. Volumes Changes in Adrenal Metastases during Delivery of 5-Fraction Stereotactic Magnetic Resonance-Guided Adaptive Radiotherapy
16. Outcomes of MR-Guided Stereotactic Body Radiotherapy (MRgSBRT) for Adrenal Metastases: A Multi-Institutional Pooled Analysis
17. Central Lung Tumors Eligible for Stereotactic Ablative Radiotherapy (SABR) Trials: Analysis of a Cohort Treated Using MR-Guided SABR
18. Tumoren van de long, mediastinum en pleura
19. Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling
20. Normal Tissue Complication Probability Modeling of Pulmonary Toxicity After Stereotactic and Hypofractionated Radiation Therapy for Central Lung Tumors
21. Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands
22. Incidence of High-Risk Radiologic Features in Patients Without Local Recurrence After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
23. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer
24. Ten years outcomes after SABR in central and ultracentral primary lung tumors
25. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
26. OC-0609 Late toxicity following stereotactic radiotherapy (SABR) for central and ultracentral lung tumors
27. PD-0068 Tumor control after MR-guided adaptive stereotactic radiotherapy for adrenal metastases
28. PO-1331 Local control rates after MR-guided single fraction SABR for lung tumors
29. Long term outcomes following chemoradiotherapy and surgery for superior sulcus tumors
30. MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC.
31. LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial.
32. Early Clinical Effectiveness, Toxicity and Quality of Life Outcomes of Magnetic Resonance Imaging-Guided Stereotactic Ablative Radiotherapy: A Systematic Review
33. Clinical Implementation of Single Visit Palliative Adaptive Radiotherapy without Prior CT Simulation
34. Does Compromising Target Coverage Impact Overall Survival when Treating Oligometastatic Disease with Stereotactic Ablative Radiotherapy (SABR)?
35. Final Results of an International Delphi Consensus Study Regarding the Optimal Management of Radiation Pneumonitis
36. 950O Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial
37. 1020P Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study
38. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
39. Artificial Intelligence-Assisted Quantitative CT Analysis of Airway Changes Following SABR for Central Lung Tumors
40. Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)
41. Definitions of Local Control after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer: A Systematic Review of the Literature
42. Treatment Toxicity and Outcomes Following Definitive Radiotherapy for Patients with Early-Stage Non-Small Cell Lung Cancers and Pre-Existing Interstitial Lung Disease – A Systematic Review
43. Feasibility of Genome-Wide Screening for Biosafety Assessment of Probiotics: A Case Study of Lactobacillus helveticus MTCC 5463
44. A Statistical Comparison of Prognostic Index Systems for Brain Metastases after Stereotactic Radiosurgery or Fractionated Stereotactic Radiation Therapy
45. Trimodality therapy for superior sulcus tumours: Evolution and evaluation of a treatment protocol
46. Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands
47. Defining Target Volumes for Stereotactic Ablative Radiotherapy of Early-stage Lung Tumours: A Comparison of Three-dimensional 18F-fluorodeoxyglucose Positron Emission Tomography and Four-dimensional Computed Tomography
48. PO-1695 Accuracy of DIR-based intra-fraction motion management in MR-guided radiotherapy
49. OC-0777 MR-guided lung SBRT: consultation, simulation and treatment delivery in a single day
50. OC-0424 Target volume time trends during daily adaptive 5-fraction MR-guided radiotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.